Evidence map›Paper›PMID 38546012›Full record

ArticleJournal of comparative effectiveness research2024

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15.

Alejandra Castanon, Benjamin D Bray, Sreeram V Ramagopalan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alejandra CastanonLane Clark & Peacock LLP, London, W1U 1DQ, UK.
Benjamin D BrayLane Clark & Peacock LLP, London, W1U 1DQ, UK.
Sreeram V RamagopalanLane Clark & Peacock LLP, London, W1U 1DQ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this latest update we discuss real-world evidence (RWE) guidance from the leading oncology professional societies, the American Society of Clinical Oncology and the European Society for Medical Oncology, and the PRINCIPLED practical guide on the design and analysis of causal RWE studies.

Indexed as

Technology Assessment, BiomedicalComparative Effectiveness ResearchHumansMedical OncologyReimbursement MechanismsResearch DesignAmerican Society of Clinical Oncologyartificial intelligenceASCOdata qualityESMOESMO-GROWEuropean Society for Medical Oncologyhealth technology assessmentinferential studiesoncologyPRINCIPLEDreal-world datareal-world evidenceregulatorytarget trial emulationUS Food and Drug Administration

Identifiers

PMID38546012
PMCPMC11037032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.